What is Zacks Research's Forecast for AXSM FY2025 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Zacks Research raised their FY2025 earnings per share estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($4.28) for the year, up from their previous forecast of ($4.40). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.34 EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.08 EPS.

A number of other research firms have also commented on AXSM. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $176.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price target on the stock. Royal Bank of Canada increased their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Finally, Robert W. Baird increased their target price on Axsome Therapeutics from $132.00 to $160.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.80.

Remove Ads

Axsome Therapeutics Trading Up 1.4 %

Axsome Therapeutics stock traded up $1.40 during mid-day trading on Wednesday, hitting $99.46. 213,633 shares of the company's stock were exchanged, compared to its average volume of 677,425. The company's 50 day simple moving average is $119.51 and its 200-day simple moving average is $102.07. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The firm has a market capitalization of $4.85 billion, a P/E ratio of -16.60 and a beta of 0.88. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AXSM. NBC Securities Inc. bought a new stake in shares of Axsome Therapeutics in the first quarter valued at about $31,000. Raiffeisen Bank International AG bought a new stake in Axsome Therapeutics in the 4th quarter valued at about $51,000. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $52,000. R Squared Ltd bought a new position in shares of Axsome Therapeutics during the fourth quarter worth approximately $64,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $76,000. Institutional investors own 81.49% of the company's stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.40% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.